IMV

Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, has obtained a loan of $5 million from the Province of
Nova Scotia, to be used to fund a portion of working capital through 2016. The
secured loan is interest bearing and repayable in 2018.


The loan will be made available in four equal installments. The first
installment of $1.25 million will be available immediately subject to
satisfaction of customary closing conditions and the remaining three
installments will be made available based on Immunovaccine meeting certain
milestones.


Immunovaccine currently has several vaccine programs in development, including
two clinical stage cancer vaccines which have both demonstrated positive immune
response and safety results in human studies. The company announced in July that
it will collaborate with Canada's NCIC Clinical Trials Group to conduct a Phase
II study of its lead cancer vaccine, DPX-Survivac, in patients with advanced
ovarian cancer. The trial is a randomized, blinded, placebo-controlled study
with DPX-Survivac in combination with low dose oral cyclophosphamide as an
immune modulator. Approximately 250 patients with ovarian cancer will be
enrolled at an estimated 20 clinical centers. The trial, expected to begin in
2014, will assess whether the vaccine can delay or prevent the recurrence of
ovarian cancer. 


DPX-Survivac will also be evaluated in a Phase II trial in glioblastoma (brain
cancer) patients starting early next year. Immunovaccine's second clinical stage
cancer vaccine, DPX-0907, is expected to begin a Phase I/II study in breast and
ovarian cancer patients during the fourth quarter of 2013. 


"We're grateful for the support of the government of Nova Scotia at this
critical moment in our development," said John Trizzino, chief executive of the
company. "Medical science is on the threshold of turning cancer into a chronic
long term illness that can be treated, and our company is at the forefront of
that revolutionary change." 


Immunovaccine has built a broad pipeline of vaccine product candidates based on
its novel DepoVax(TM) adjuvanting platform, a patented agent that makes vaccines
become more effective more quickly, reach higher levels of protection and last
longer. In addition to its clinical stage cancer vaccines, the company is
leveraging DepoVax(TM) for the development of vaccines against anthrax and
respiratory syncytial virus (RSV), among other targets. Immunovaccine is also
active in the area of animal health vaccines, having established key
partnerships in the sector with leaders such as Zoetis (formerly Pfizer Animal
Health).


About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the US
National Cancer Institute (NCI) as a promising tumor-associated antigen (TAA)
because of its therapeutic potential and its cancer specificity. Survivin is
broadly over-expressed in multiple cancer types in addition to ovarian cancer,
including breast, colon and lung cancers. Survivin plays an essential role in
antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting
resistance to various anti-cancer therapies. Survivin is also a prognostic
factor for many cancers and it is found in a higher percentage of tumors than
other TAAs.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to actively
and specifically search for and destroy tumor cells. Survivin-specific T cells
have been shown to target and kill survivin-expressing cancer cells while
sparing normal cells.


About DepoVax(TM)

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax(TM) platform possesses impressive flexibility,
allowing it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into
Phase I human clinical trials. The Company is also advancing a broad infectious
diseases pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at
www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
John Trizzino
CEO
(902) 492-1819
info@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

(TSXV:IMV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024